Esperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0.03 EPS

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03, MarketWatch Earnings reports. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the […]

Related Keywords

United States ,America , ,Esperion Therapeutics Inc ,Jpmorgan Chase Co ,Wasatch Advisors Inc ,Armistice Capital ,Needham Company ,Esperion Therapeutics Company Profile ,Millennium Management ,Jacobs Levy Equity Management Inc ,Esperion Therapeutics ,Get Free Report ,Marketwatch Earnings ,Levy Equity Management ,Esperion Therapeutics Daily ,Nasdaq Espr ,Sespr ,Medical ,Earnings ,